Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer

The study plans to randomized eligible and consent patients in two balanced parallel groups, the one defined as the experimental arm while the second consisting in the actual standard of care is defined as the control standard arm.

The experimental arm consists in 12 weeks of capecitabine combined with SIRT as neoadjuvant treatment followed by surgery. After SIRT, patients will be assessed at 10 weeks with thoracic-abdominal and pelvic CT scan and liver MRI. If the tumour is still deemed resectable, surgery will be performed at 16 weeks.

In case of discovery of contra-indication to SIRT after inclusion (such as described in the SIRT exclusion criteria section) patients will stop chemotherapy and proceed to surgery within one month. The concerned patients are still included in the study and continue the post-surgery follow-up as expected by the protocol.

In the control arm, patients will proceed to upfront surgery.

The follow - up period begins just after the surgery in both arm, and the patients are evaluated every 3 months for 2 years, then every 6 months for 3 additional years, clinically by an oncologist and radiologically with thoracic-abdominal and pelvic CT scan.

Whether progression occurred, patients will no longer be followed according to the protocol; only vital status continues to be collected until the end of the study (i.e. the last visit of the last patient).

Inclusion criteria

• Age > 18 years-old,
• ECOG Performance Status <2,
• Histologically-proven ICC,
• No previous treatment for ICC,
• Tumour deemed resectable by a hepatobiliary surgeon, validated by a Surgical Review Board,
• Significant risk of close margins, defined as:

• Resection margin predicted by the surgeon <1 cm
• Tumour >5 cm
• Multifocal lesion deemed resectable, validated by a Surgical Review Board
• Registration with a social security scheme,
• Patient information and signature of informed consent or legal representative.

Non-inclusion Criteria:

• Severe fibrosis (F3) ou cirrhosis (F4),
• Inadequate haematological, hepatic, renal and coagulation functions:

• Haemoglobin ≤ 8,5 g/dl
• Neutrophils < 1,5 Giga/L
• Platelets < 60 Giga/L
• Bilirubin > 34 µmol/L
• ASAT/ALAT > 5 x ULN
• Creatinine clearance < 30 ml/min (MDRD)
• TP et INR > 2,3 ULN
• TCA > 1,5 x ULN
• Uracil blood level >16 ng/mL,
• Respiratory insufficiency,
• Comorbidity precluding surgical resection, such as severe heart disease,
• Presence of microvacuolar steatosis > 60% or regenerative nodular hyperplasia, for patients for whom a major hepatectomy is planned,
• Contraindication to hepatic artery catheterization (vascular abnormalities, bleeding diathesis),
• Previous chemotherapy (including for another cancer),
• Previous abdominal (supra-mesocolic) radiotherapy (including for another cancer),
• Other invasive malignancies,
• Patient participate to an interventional study that tests another medical intervention before surgery,
• Pregnant woman or likely to be or breastfeeding, or male or female patients of reproductive potential without effective contraception from screening to 30 days after the end of the treatment adjuvant,
• Minors, individual deprived of liberty, or under any kind of guardianship,
• Patients unable to submit to medical follow-up of the study for social, medical or psychological reasons.

Exclusion criteria

• Pulmonary shunt with dose >30Gy,
• Digestive shunting, non-correctible by interventional radiology,
• Absence of fixation of MAA in the tumour.